Drug Trial Radar · NCT07185776
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Last checked: Nov 20, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
203
Actual
Start
Oct 21, 2025
Primary completion
Apr 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
Conditions
- Lipoprotein Disorder
Interventions
HRS-5632 InjectionDrug
HRS-5632 injection.
HRS-5632 Injection PlaceboDrug
HRS-5632 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent change from the baseline in Lipoprotein (a) (Lp(a)).Time frame: From baseline to Day 360.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of AFMU
Xi’an, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.